Meta-Analysis: The Effect of Diabetes Mellitus Comorbidity on the Risk of Death in Covid-19 Patients

Authors

  • Utin Ilma Agni Kun'ain Masters Program in Public Health, Universitas Sebelas Maret
  • Setyo Sri Rahardjo Faculty of Medicine, Universitas Sebelas Maret
  • Didik Gunawan Tamtomo Faculty of Medicine, Universitas Sebelas Maret

Abstract

Background: Corona Virus Deases 2019 (COVID-19) is an infectious disease caused by the corona virus. COVID-19 is currently a challenge for diabetes patients. Diabetes mellit­us predisposes to a very severe disease course and increases the risk of death from COVID-19. This study aims to estimate the average mag­ni­tude of the effect of diabetes mellitus comor­bi­dity on the risk of death of COVID-19 patients.

Subjects and Method: This was a systematic review and meta-analysis. This research was conducted using secondary data that will be conducted by searching and selecting data from the results of clinical trials conducted around the world. Search for articles through syste­matic and comprehensive databases from Pub­med, Google Scholar, Springer Link. The ana­lysis in this study was carried out using the Review Manager 5.3 software. The results of the analysis are the effect size, heterogeneity and then the study model. Variations between studies are used to determine the analysis model which is divided into two models, namely the fixed effect model (FEM) and the random effect model (REM).

Results: Based on the results of the analysis, there was high heterogeneity between experi­ments (I2= 85%; p= 0.04), so that the Random Effects Model (REM) was used. COVID-19 patients with comorbid diabetes mellitus were 2.17 times more likely to die than patients without comorbid diabetes mellitus (aOR 2.17; 95% CI 1.04 to 4.54).

Conclusion: Diabetes mellitus co-morbidity increases 2.17 times the risk of death in COVID-19 patients compared to patients without dia­betes mellitus comorbidity.

Keywords: COVID-19, Comorbidity, Diabetes Mellitus, Death

Correspondence: Utin Ilma Agni Kun'ain. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36 A, Surakarta 57126, Central Java. Email: utinilmaagni8p@gmail.com. Mobile: +628111044542.

Indonesian Journal of Medicine (2020), 05(04): 368-377
https://doi.org/10.26911/theijmed.2020.05.04.12.

 

References

Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z (2020). Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 166: 108347. doi: 10.1016/j.diabres.2020.-108347.

Aggarwal G, Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F (2020). Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Journal of Diabetes. 12(11): 851–855. doi: 10.-1111/1753-0407.13091.

Budiarti E, Tamtomo DG, Adriani RB (2017). Path analysis on the biopsy-chosocial determinants of type 2 dia-betes mellitus and depression at Dr. Moewardi Hospital, Surakarta. J Epidemiol Public Health. 03(01): 1–14. doi: 10.26911/jepublichealth.2018-.03.01.01.

Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, et al. (2020). Clinical characteristics and outcomes of pati-ents with diabetes and covid-19 in association with glucose-lowering medication. Diabetes care. 43: 1399–1407. doi: 10.2337/dci20-0035.

Das S, Anu KR, Birangal S, Nikam AN, Pan-dey A, Mutalik S, Joseph A (2020). Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life sciences. 258: 118202. doi: 10.1016/j.lfs.2020.118202.

Erener S (2020). Diabetes, infection risk and COVID-19. Molecular Metabo-lism. 101044. doi: 10.1016/j.molmet.-2020.101044.

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, Yuan Q, et al. (2020). The epidemiology and clinical information about COVID-19. European Journal of Clinical Microbiology and Infectious Diseases. 1011–1019. doi: 10.1007/-s10096-020-03874-z.

Handoko, Setyo SR, Murti B (2018). Pre-dictors of macro and microvascular complication in type 2 diabetes melli-tus patients at Dr. Moewardi Hospital, Surakarta. Indones J Med. 3(1): 1–13. doi: 10.26911/theijmed.2018.03.01.01.

Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, et al. (2020). Coronavirus disease 2019 (COVID-19): A literature review. Jo-urnal of Infection and Public Health. 667–673. doi: 10.1016/j.jiph.2020.03-.019.

Jeong IK, Yoon KH, Lee MK (2020). Dia-betes and COVID-19: Global and regi-onal perspectives. Diabetes Research and Clinical Practice. 166. doi: 10.-1016/j.diabres.2020.-108303.

Li G, Deng Q, Feng J, Li F, Xiong N, He Q (2020). Clinical characteristics of dia-betic patients with COVID-19. Journal of Diabetes Research. doi: 10.1155/-2020/165-2403.

Marhl M,Grubelnik V,MagdicM,Markovic R (2020). Diabetes and metabolic syn-drome as risk factors for COVID-19. Clinical Research and Reviews. 14(4): 671–677. doi: 10.1016/j.-dsx.2020.0-5.013.

Miller LE, Bhattacharyya R, Miller AL (2020). Diabetes mellitus increases the risk of hospital mortality in pati-ents with Covid-19: Systematic review with meta-analysis. Medicine. NLM (Medline), 99(40): e22439. doi: 10.1-097/MD.0-000000000022439.

Moon S, Lee K, Park J, Yun S, Lee YS, Lee DS (2020). Clinical characteristics and mortality predictors of COVID-19 patients hospitalized at Nationally-Designated Treatment Hospitals. Journal of Korean medical science. NLM (Medline), 35(36), p. e328. doi: 10.3346/jkms.2020.35.e328.

Pascarella G, Strumia A, Piliego C, Bruno F, Del BR, Costa F, Scarlata S, et al. (2020). COVID-19 diagnosis and ma-nagement: a comprehensive review. Journal of Internal Medicine. 288(2): 192–206. doi: 10.1111/joim.13091.

Pedrosa MS, Neves NF (2020). COVID-19 and diabetes: What should we ex-pect?. Journal of Diabetes Science and Technology. 1133–1134. doi: 10.1177/1932296-820948041.

Peric S, Stulnig TM (2020). Diabetes and COVID-19: Disease—Management—People. Wiener Klinische Wochen-schrift. Springer Medizin, 132(13–14): 356–361. doi: 10.1007/s00508-020-01672-3.

Pranoto HP, Tamtomo D, Murti B (2017). The roles of medical doctor and family on patient health behavior in controlling HbA1C level among patients with type 2 diabetes mellitus at Dr. Moewardi Hospital. Indonesian Journal of Medicine. 02(01): 21–34. doi: 10.26911/theijmed.2017.02.01.03.

Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, Yu X, Zhang S (2020). Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovascular Diabetology. BioMed Central: 1–8. doi: 10.11-86/s12933-020-01035-2.

Sun J, He W, Wang L, Lai A, Ji X, Zhai X, Li G, et al. (2020). COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends in Molecular Medicine. 483–495. doi: 10.1016/j.molmed.2020.02.008.

Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, Yu X, et al. (2020). Clinical characteristics and outcomes of pati-ents with severe covid-19 with dia-betes. BMJ Open Diabetes Research and Care. BMJ Publishing Group, 8(1): 1343. doi: 10.1136/bmjdrc-2020-001343.

Yu C, Lei Q, Li W, Wang X, Liu W, Fan X, Li W (2020). Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: A retrospec-tive study in Wuhan, China. American Journal of Preventive Medicine. 59(2). doi: 10.1016/j.amepre.2020.05.002.

Zhou W, Ye S, Wang W, Li S, Hu Q, Masaki T (2020). Clinical features of COVID-19 patients with diabetes and second-ary hyperglycemia. Journal of Diabe-tes Research. Hindawi Limited, 2020: 1–9. doi: 10.1155/2020/3918723.

Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, et al (2020). Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabolism. Cell Press, 31(6): 1068-1077.-e3. doi: 10.1016/j.cmet.2020.-04.021.

Downloads

Published

2021-01-27

Issue

Vol. 5 No. 4 (2020)

Section

Articles